AVITA MED LTD/S (OTCMKTS:AVMXY) had its target price raised by Lake Street Capital from $8.00 to $10.00 in a research report report published on Wednesday, The Fly reports. Lake Street Capital currently has a buy rating on the medical device company’s stock.

AVMXY opened at $8.03 on Wednesday. The business’s 50 day moving average is $6.12 and its 200-day moving average is $5.41. The stock has a market cap of $656.01 million, a PE ratio of -20.59 and a beta of 1.28. AVITA MED LTD/S has a twelve month low of $1.06 and a twelve month high of $8.58.

AVITA MED LTD/S Company Profile

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin.

Read More: Compound Interest

The Fly

Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.